Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Sirona Biochem Corp
V.SBM
Alternate Symbol(s):
SRBCF
Healthcare
Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to...
large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:SBM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
...
Next
(101)
•••
biorun
X
View Profile
View Bullboard History
Comment by
biorun
on Jul 02, 2022 8:55am
RE:RE:RE:RE:Pretty disappointing if you ask me.
I agree this is how it typically works on the venture. We have seen in past the aftermath with pre and post reactions in share volumes. However, this is Abbvie, a dead serious public entity, now in
...more
(11)
•••
Transperance
X
View Profile
View Bullboard History
Post by
Transperance
on Jul 02, 2022 6:42am
Concerns going forward
Don’t think that Institutions will buy shares at present due to the weak Board of Directors. The BoD consists of CEO, CFO and CSO from Sirona management plus one anonymous MD and one anonymous Chinese
...more
Discover Options Trading Strategies to Minimize your Tax Burden
posted Dec 01, 2024 9:00am by
Bank of Montreal
-
|
Options trading doesn’t come without tax implications, but there are ways investors can still optimize their after-tax returns with just a little bit of understanding. Approaches for investors to keep in mind are holding periods, wash-sales rule, tax advantaged accounts, and qualified cover calls. BMO’s enhanced InvestorLine platform. Industry-leading tools and capabilities specifically designed to empower options traders. ...read more
(75)
•••
forhandlaren
X
View Profile
View Bullboard History
Comment by
forhandlaren
on Jul 02, 2022 4:05am
RE:RE:Pretty disappointing if you ask me.
I think that the PRC Partners analysis was not very helpful. Sure, I can understand that without actual numbers it's not possible to calculate a proper valuation.But when one don't know, one
...more
(101)
•••
biorun
X
View Profile
View Bullboard History
Comment by
biorun
on Jul 01, 2022 10:35am
RE:Pretty disappointing if you ask me.
The deal is pretty awesome Tickle, you just need a little patience until all the details come to light. We are all disappointed with the initial market reaction, a reasonable expectation for
...more
(11)
•••
Transperance
X
View Profile
View Bullboard History
Comment by
Transperance
on Jul 01, 2022 3:22am
RE:RE:RE:Why has Abbdie not said anything about the deal?
One can only speculate. One speculation is that Abbvie don’t want the community to get to much attention to the deal due to Abbvie´s interest in the anti-wrinkle compound, going forward.
(4)
•••
bazooka73
X
View Profile
View Bullboard History
Comment by
bazooka73
on Jul 01, 2022 2:08am
RE:RE:Why has Abbdie not said anything about the deal?
I think the question was not why AbbVie doesn't disclose any numbers about the deal but why the didn't mention the deal at all. Maybe for some confidentiality/competitor reasons? We don't
...more
(75)
•••
forhandlaren
X
View Profile
View Bullboard History
Comment by
forhandlaren
on Jul 01, 2022 1:46am
RE:TFC-1394
I assume that the difference is that TFC-1067 targets dark spots on the skin - hyperpigmentstion - in order to lighten them without affecting the surrounding area. It would make sense if TFC-1394 is
...more
(101)
•••
biorun
X
View Profile
View Bullboard History
Comment by
biorun
on Jul 01, 2022 12:05am
RE:Why has Abbdie not said anything about the deal?
here is the explanation: https://stockhouse.com/companies/bullboard/v.sbm/sirona-biochem-corp?postid=34793327
(1064)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Jun 30, 2022 11:20pm
RE:Why has Abbdie not said anything about the deal?
I guess the 'v' is reasonably close to the 'd' if that explains it.
(1978)
•••
lscfa
X
View Profile
View Bullboard History
Post by
lscfa
on Jun 30, 2022 8:06pm
Patented Compounds
Looks like 1067 is one of nine. How many are useful to be seen. see image. https://patents.google.com/patent/US10351501B2/en?oq=15%2f551%2c686
(1978)
•••
lscfa
X
View Profile
View Bullboard History
Post by
lscfa
on Jun 30, 2022 7:17pm
TFC-1394
Just how the hell does it differ from TFC-1067? January 4, 2022 TFC-1394 Individual countries have regulatory requirements which can differ from the rest of
...more
(75)
•••
forhandlaren
X
View Profile
View Bullboard History
Post by
forhandlaren
on Jun 30, 2022 4:50pm
What exactly is included in the AbbVie deal?
...Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona's patents for TFC-1067 and related family of compounds
...more
(101)
•••
biorun
X
View Profile
View Bullboard History
Comment by
biorun
on Jun 30, 2022 4:14pm
RE:Risk to reward
Agree. And we will also have 2 other potential deals on the horizon, in massive markets. The company mentioned to me in response to a question that working with Abbvie has been a completely
...more
(101)
•••
biorun
X
View Profile
View Bullboard History
Post by
biorun
on Jun 30, 2022 3:43pm
Still Strong Buy - 96%
Based upon computer and AI analytics. Nice to see this in the context of majors being 100% sell across the board. https://www.barchart.com/stocks/quotes/SBM.VN/overview
Prev
...
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >